Skip to content

Study · Not a test of the peptide alone · 2006

8 results

[Clinical study and long-term evaluation of immunomodulation therapy on trauma, severe sepsis and multiple organ dysfunction syndrome patients].

Huang SW, Guan XD, Chen J, Ou Yang B

Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue1 Nov 2006Cited by 5 (Europe PMC)

PMID17092412 (opens in a new tab)PepBankPUB-17092412
Publisher pageAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In patients with trauma, severe sepsis and MODS, fewer patients died in hospital with ulinastatin plus thymosin-alpha1 than with regular therapy alone.

    In plain wordsIn patients with trauma, severe sepsis and organ failure, fewer died in hospital with an ulinastatin plus thymosin-alpha1 regimen than with regular therapy.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIn-hospital mortality
    Study

    n = 70

    Comparator
    Regular therapy
    Outcome group
    Mortality · Infection

    Source sentences

    Summary
    During hospitalization, 20 patients died in the control group and 13 patients died in the treatment group. There was significant difference between two groups (P<0.05).
    2 context sentences
    Summary · context
    Prospective, randomized, blind and controlled clinical analysis of 70 patients conforming to the enrolled standard was carried out.
    Summary · context
    One was control group (n=34) with regular therapy, and the treatment group (n=36) with ulinastatin plus thymosin-alpha1 on the base of regular therapy for 1 week.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In patients with trauma, severe sepsis and MODS, lymphocyte counts were higher with ulinastatin plus thymosin-alpha1 than with regular therapy from day 7 to day 28.

    In plain wordsIn patients with trauma, severe sepsis and organ failure, lymphocyte counts were higher with an ulinastatin plus thymosin-alpha1 regimen than with regular therapy.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseLymphocyte count
    Study

    n = 70

    Comparator
    Regular therapy
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    After 7 up to 28 days of therapy, the counts of lymphocyte and CD14(+) monocytes HLA-DR were significantly higher than those in control group (all P<0.05).
    2 context sentences
    Summary · context
    Prospective, randomized, blind and controlled clinical analysis of 70 patients conforming to the enrolled standard was carried out.
    Summary · context
    One was control group (n=34) with regular therapy, and the treatment group (n=36) with ulinastatin plus thymosin-alpha1 on the base of regular therapy for 1 week.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In patients with trauma, severe sepsis and MODS, CD14+ monocyte HLA-DR was higher with ulinastatin plus thymosin-alpha1 than with regular therapy from day 7 to day 28.

    In plain wordsIn patients with trauma, severe sepsis and organ failure, a monocyte immune marker was higher with an ulinastatin plus thymosin-alpha1 regimen than with regular therapy.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD14+ monocyte HLA-DR
    Study

    n = 70

    Comparator
    Regular therapy
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    After 7 up to 28 days of therapy, the counts of lymphocyte and CD14(+) monocytes HLA-DR were significantly higher than those in control group (all P<0.05).
    2 context sentences
    Summary · context
    Prospective, randomized, blind and controlled clinical analysis of 70 patients conforming to the enrolled standard was carried out.
    Summary · context
    One was control group (n=34) with regular therapy, and the treatment group (n=36) with ulinastatin plus thymosin-alpha1 on the base of regular therapy for 1 week.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In patients with trauma, severe sepsis and MODS, mechanical ventilation was shorter with ulinastatin plus thymosin-alpha1 than with regular therapy.

    In plain wordsIn patients with trauma, severe sepsis and organ failure, time on a ventilator was shorter with an ulinastatin plus thymosin-alpha1 regimen than with regular therapy.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseDuration of mechanical ventilation
    Study

    n = 70

    Comparator
    Regular therapy
    Outcome group
    Intensive care and hospital outcomes · Whole body

    Source sentences

    Summary
    The duration of using mechanical ventilation and pressor agent in the treatment group were shorter than those in the control group
    2 context sentences
    Summary · context
    Prospective, randomized, blind and controlled clinical analysis of 70 patients conforming to the enrolled standard was carried out.
    Summary · context
    One was control group (n=34) with regular therapy, and the treatment group (n=36) with ulinastatin plus thymosin-alpha1 on the base of regular therapy for 1 week.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In patients with trauma, severe sepsis and MODS, pressor agent use was shorter with ulinastatin plus thymosin-alpha1 than with regular therapy.

    In plain wordsIn patients with trauma, severe sepsis and organ failure, blood pressure drug use was shorter with an ulinastatin plus thymosin-alpha1 regimen than with regular therapy.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseDuration of pressor agent use
    Study

    n = 70

    Comparator
    Regular therapy
    Outcome group
    Intensive care and hospital outcomes · Cardiovascular

    Source sentences

    Summary
    The duration of using mechanical ventilation and pressor agent in the treatment group were shorter than those in the control group (both P<0.01).
    2 context sentences
    Summary · context
    Prospective, randomized, blind and controlled clinical analysis of 70 patients conforming to the enrolled standard was carried out.
    Summary · context
    One was control group (n=34) with regular therapy, and the treatment group (n=36) with ulinastatin plus thymosin-alpha1 on the base of regular therapy for 1 week.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In patients with trauma, severe sepsis and MODS, ICU length of stay was not significantly increased with ulinastatin plus thymosin-alpha1.

    In plain wordsIn patients with trauma, severe sepsis and organ failure, an ulinastatin plus thymosin-alpha1 regimen did not significantly lengthen ICU stay.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeICU length of stay
    Study

    n = 70

    Comparator
    Regular therapy
    Outcome group
    Intensive care and hospital outcomes · Whole body

    Source sentences

    Summary
    The length of stay and the cost in the intensive care unit (ICU) were not significantly increased in the treatment group (both P>0.05).
    2 context sentences
    Summary · context
    Prospective, randomized, blind and controlled clinical analysis of 70 patients conforming to the enrolled standard was carried out.
    Summary · context
    One was control group (n=34) with regular therapy, and the treatment group (n=36) with ulinastatin plus thymosin-alpha1 on the base of regular therapy for 1 week.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 07HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In patients with trauma, severe sepsis and MODS, ICU cost was not significantly increased with ulinastatin plus thymosin-alpha1.

    In plain wordsIn patients with trauma, severe sepsis and organ failure, an ulinastatin plus thymosin-alpha1 regimen did not significantly raise ICU cost.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeICU cost
    Study

    n = 70

    Comparator
    Regular therapy
    Outcome group
    Intensive care and hospital outcomes · Whole body

    Source sentences

    Summary
    The length of stay and the cost in the intensive care unit (ICU) were not significantly increased in the treatment group (both P>0.05).
    2 context sentences
    Summary · context
    Prospective, randomized, blind and controlled clinical analysis of 70 patients conforming to the enrolled standard was carried out.
    Summary · context
    One was control group (n=34) with regular therapy, and the treatment group (n=36) with ulinastatin plus thymosin-alpha1 on the base of regular therapy for 1 week.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  8. 08HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In patients with trauma, severe sepsis and MODS, long-term survival time was longer with ulinastatin plus thymosin-alpha1 than with regular therapy.

    In plain wordsIn patients with trauma, severe sepsis and organ failure, long-term survival was longer with an ulinastatin plus thymosin-alpha1 regimen than with regular therapy.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseLong-term survival time
    Study

    n = 70

    Comparator
    Regular therapy
    Outcome group
    Mortality · Infection

    Source sentences

    Summary
    The long-term survival time in the treatment group was much longer than that in the control group (P<0.05).
    2 context sentences
    Summary · context
    Prospective, randomized, blind and controlled clinical analysis of 70 patients conforming to the enrolled standard was carried out.
    Summary · context
    One was control group (n=34) with regular therapy, and the treatment group (n=36) with ulinastatin plus thymosin-alpha1 on the base of regular therapy for 1 week.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.